Genetics and iron in the systems biology of Parkinson’s disease and some related disorders
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The systems biology approach to complex diseases recognises that a potentially large number of biochemical network elements may be involved in disease progression, especially where positive feedback loops can be identified. Most of these network elements will be encoded by genes, for which different alleles may affect the network(s) differentially. A primary requirement is therefore to determine the relevant gene-network relationships. A corollary of this is that identification of the network should thereby allow one to 'explain' or account for any genetic associations. We apply this approach to Parkinson's disease, a disease characterised by apoptotic death of neurons of the substantia nigra, and coupled significantly to a derangement of iron metabolism. We thereby account for the involvement of various genes and biochemical pathways associated with Parkinsonism, including seemingly unconnected ones involving iron, α-synuclein, parkin, mitochondrial respiration and biology, ceramide production, lysosome biology, Lewy body formation, and so on. Although such an analysis necessarily recognises that there is no unitary 'cause' of Parkinson's, it also recognises that each of the elements contributing can or does effectively converge on a particular mode of apoptotic cell death in dopaminergic neurons, often involving iron-mediated hydroxyl radical formation. Overall, the systems biology approach allows us to propose at least one coherent synthesis of the rather disparate literature surrounding the aetiology of Parkinson's disease, and thereby to suggest some (synergistic) targets for ameliorating the disease and its progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Uttara, B., Singh, A., Zamboni, P., & Mahajan, R. (2009) · Current Neuropharmacology · doi:10.2174/157015909787602823 · Cited by 3,378 · cited 1×
“…(Aquilano et al., 2008; Du et al., 2012; Gogoi et al., 2011; Kell, 2009b, 2010a; Oshiro et al., 2011; Pandey et al., 2012; Reale et al., 2012; Uttara et al., 2009; Wang et al., 2012; Zbarsky et al., 2005), albeit some antioxidants (such as various cysteine derivatives (Napolitano et al.,…”
A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics
Kohanski, M. A., Dwyer, D. J., Hayete, B., Lawrence, C. A., & Collins, J. J. (2007) · Cell · doi:10.1016/j.cell.2007.06.049 · Cited by 2,982 · cited 1×
“A particularly nice example involving unliganded iron and hydroxyl radical provides exactly the explanation of why bactericidal antibiotics differ mechanistically from those that are merely bacteriostatic (Dwyer et al., 2009; Kell, 2010b; Kohanski et al., 2007).”
Kitano, H. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1471 · Cited by 2,278
Computational systems biology.
Kitano, H. (2002) · Nature · doi:10.1038/nature01254 · Cited by 2,209
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationIron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788 · cited 1×
“Both interact with components responsible for fission and fusion of the mitochondria (Clark et al., 2006; Park et al., 2006; Poole et al., 2008; Yang et al., 2008).”
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 1×
“Both interact with components responsible for fission and fusion of the mitochondria (Clark et al., 2006; Park et al., 2006; Poole et al., 2008; Yang et al., 2008).”
A N EW A PPROACH TO D ECODING L IFE : Systems Biology
Ideker, T., Galitski, T., & Hood, L. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.343 · Cited by 1,664 · cited 1×
“The term ‘systems biology’ describes an approach to understanding biology that places emphasis on the interactions between the components known via molecular biology, rather than on the components themselves (Hood, 2003; Ideker et al., 2001; Kitano, 2002).”
The Haber–Weiss reaction and mechanisms of toxicity
Kehrer, J. P. (2000) · Toxicology · doi:10.1016/s0300-483x(00)00231-6 · Cited by 1,418 · cited 2×
“The process of neurodegeneration may thus be accelerated by increased levels of iron, especially Fe(II) reacting with H2O2 to form OH via the Fenton reaction and favouring a greater turnover of the Haber–Weiss cycle which leads to an amplification of oxidative stress (Gerlach et al., 1994; Riederer and Youdim, 1993) w…”
A Review of the Antioxidant Mechanisms of Polyphenol Compounds Related to Iron Binding
Perron, N. R., & Brumaghim, J. L. (2009) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-009-9043-x · Cited by 1,370 · cited 1×
“…et al., 2009; Guo et al., 2007; Jomova et al., 2010b; Jomova and Valko, 2011b; Kell, 2009a, 2010a; Levites et al., 2001; Mak, 2012; Mandel et al., 2008; Mandel and Youdim, 2012; Ortega-Arellano et al., 2011; Perron and Brumaghim, 2009; Tan et al., 2008; Tanaka et al., 2011; Weinreb et al., 2004).”
Butelli, E., Titta, L., Giorgio, M., Mock, H.-P., Matros, A., Peterek, S., Schijlen, E. G. W. M., Hall, R. D., Bovy, A. G., Luo, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1506 · Cited by 1,238
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 3×
“(Smith et al., 2005; West et al., 2005), additionally associated with the plasma membrane, lipid rafts, synaptic vesicles, the Golgi appa-”
Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease
Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M.-Y., & Bonini, N. M. (2002) · Science · doi:10.1126/science.1067389 · Cited by 1,227 · cited 1×
“LBs contain nearly 80 other proteins (Licker et al., 2009), amongst others ubiquitin (Kuzuhara et al., 1988), proteasome subunits (Ii et al., 1997), heat shock proteins (Auluck et al., 2002) and neurofilaments (Galvin et al., 1997).”
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149 · cited 2×
“A very large literature [e.g. (Barnham and Bush, 2008; Boelmans et al., 2012; Bolognin et al., 2009b; Crichton et al., 2011; Dexter et al., 1989; Galazka-Friedman et al., 2012; Jomova et al., 2010a; Kell, 2009b, 2010b; Mochizuki and Yasuda, 2012; Nunez et al., 2012; Perez et al., 2008; Rhodes and…”
The segment polarity network is a robust developmental module
von Dassow, G., Meir, E., Munro, E. M., & Odell, G. M. (2000) · Nature · doi:10.1038/35018085 · Cited by 1,144 · cited 1×
“…topologies of biochemical networks for robustness, since any single-point-failure of the system is likely to be selected against [e.g. (Bornholdt and Sneppen, 2000; Kitano, 2004; Shinar and Feinberg, 2010; Stelling et al., 2004; van Nimwegen et al., 1999; von Dassow et al., 2000; Wagner, 2005)].”
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Robustness of cellular functions
Stelling, J., Sauer, U., Szallasi, Z., Doyle, F. J., & Doyle, J. (2004) · Cell · doi:10.1016/j.cell.2004.09.008 · Cited by 1,049
The systems biology graphical notation.
Novère, N. L., Hucka, M., Mi, H., Moodie, S., Schreiber, F., Sorokin, A., Demir, E., Wegner, K., Aladjem, M. I., Wimalaratne, S. M., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1558 · Cited by 903
Self-citationThe PINK1/Parkin pathway regulates mitochondrial morphology
Poole, A. C., Thomas, R. E., Andrews, L. A., McBride, H. M., Whitworth, A. J., & Pallanck, L. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709336105 · Cited by 885 · cited 1×
“Both interact with components responsible for fission and fusion of the mitochondria (Clark et al., 2006; Park et al., 2006; Poole et al., 2008; Yang et al., 2008).”
Automated design of ligands to polypharmacological profiles
Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X.-P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., et al. (2012) · Nature · doi:10.1038/nature11691 · Cited by 832 · cited 1×
“…of substances of interest in biotechnology, as in (Butelli et al., 2008; Park et al., 2007), and why the most effective pharmaceutical drugs (have to) act at multiple points (Besnard et al., 2012; Hopkins et al., 2006; Hopkins, 2008; Lehár et al., 2007; Lehár et al., 2008; Small et al., 2011).”
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
A common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, W. P., Abou-Sleiman, P. M., Gandhi, S., Jain, S., Singleton, A., Lees, A. J., Shaw, K., Bhatia, K. P., Bonifati, V., Quinn, N. P., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17830-1 · Cited by 774
Toxin-induced models of Parkinson’s disease
Bové, J., Prou, D., Perier, C., & Przedborski, S. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.484 · Cited by 739 · cited 1×
“One mechanism contributing to oxidative stress in PD involves an impairment of mitochondrial function, especially of complex I activity (Bové et al., 2005; Danielson et al., 2011; Dawson and Dawson, 2003; Fato et al., 2008b; Henchcliffe and Beal, 2008; Perier et al., 2007; Schapira et al., 1989;…”
Metals in Alzheimer's and Parkinson's Diseases
Barnham, K. J., & Bush, A. I. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.02.019 · Cited by 695 · cited 1×
“A very large literature [e.g. (Barnham and Bush, 2008; Boelmans et al., 2012; Bolognin et al., 2009b; Crichton et al., 2011; Dexter et al., 1989; Galazka-Friedman et al., 2012; Jomova et al., 2010a; Kell, 2009b, 2010b; Mochizuki and Yasuda, 2012; Nunez et al., 2012; Perez et al., 2008; Rhodes and…”
Mitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., Volitakis, I., Liu, X., Smith, J. P., Perez, K., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.018 · Cited by 672
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., & Ross, C. A. (2006) · Nature Neuroscience · doi:10.1038/nn1776 · Cited by 619 · cited 15×
“Within the LRRK2 gene many variations (point mutations) of unknown significance have been identified in almost all domains (Chung et al., 2011).”
InfluentialTau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594 · cited 1×
“These data suggest that there might be a contribution of tau to the toxic neuronal iron accumulation in PD (Lei et al., 2012).”
Park, J. H., Lee, K. H., Kim, T. Y., & Lee, S. Y. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702609104 · Cited by 592 · cited 2×
“…affected to raise biochemical fluxes for increasing the rate of production of substances of interest in biotechnology, as in (Butelli et al., 2008; Park et al., 2007), and why the most effective pharmaceutical drugs (have to) act at multiple points (Besnard et al., 2012; Hopkins et al., 2006;…”
Herrgård, M. J., Swainston, N., Dobson, P., Dunn, W. B., Arga, K. Y., Arvas, M., Blüthgen, N., Borger, S., Costenoble, R., Heinemann, M., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1492 · Cited by 588
Self-citationFenton Chemistry: An Introduction
Wardman, P., & Candeias, L. P. (1996) · Radiation Research · doi:10.2307/3579270 · Cited by 587
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Self-citationDo, C. B., Tung, J. Y., Dorfman, E., Kiefer, A. K., Drabant, E. M., Francke, U., Mountain, J. L., Goldman, S. M., Tanner, C. M., Langston, J. W., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002141 · Cited by 515
Barja, G. (1999) · Journal of Bioenergetics and Biomembranes · doi:10.1023/a:1005427919188 · Cited by 494 · cited 1×
“…hydrogen peroxide and superoxide are both produced by mitochondria in very large amounts [e.g. (Adam-Vizi, 2005; Adam-Vizi and Chinopoulos, 2006; Barja, 1999; Fato et al., 2008a; Orrenius et al., 2007; Raha and Robinson, 2001; Turrens, 2003)], and can react with iron when it is in unliganded or…”
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
Dobson, P. D., & Kell, D. B. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2438 · Cited by 475 · cited 1×
“There are also issues connected with getting such drugs to their actual sites of action (Dobson and Kell, 2008; Kell et al., 2011, 2012).”
Self-citationCan we rationally design promiscuous drugs?
HOPKINS, A., MASON, J., & OVERINGTON, J. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.01.013 · Cited by 469
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease
Nichols, W. C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C. A., Michaels, V. E., Reed, T., Rudolph, A., Shults, C. W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17828-3 · Cited by 457
Adam-Vizi, V. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1140 · Cited by 439
Salazar, J., Mena, N., Hunot, S., Prigent, A., Alvarez-Fischer, D., Arredondo, M., Duyckaerts, C., Sazdovitch, V., Zhao, L., Garrick, L. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804373105 · Cited by 409
Clinical and genetic delineation of neurodegeneration with brain iron accumulation
Gregory, A., Polster, B. J., & Hayflick, S. J. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061929 · Cited by 364
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Self-citationPINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons
Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. S. Y., Miljan, E. A., Keen, G., Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002455 · Cited by 316 · cited 1×
“PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons (Wood-Kaczmar et al., 2008).”
Mitochondria, oxygen free radicals, and apoptosis
Raha, S., & Robinson, B. H. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1398 · Cited by 306 · cited 1×
“…superoxide are both produced by mitochondria in very large amounts [e.g. (Adam-Vizi, 2005; Adam-Vizi and Chinopoulos, 2006; Barja, 1999; Fato et al., 2008a; Orrenius et al., 2007; Raha and Robinson, 2001; Turrens, 2003)], and can react with iron when it is in unliganded or poorly liganded forms.”
Lysosomes in iron metabolism, ageing and apoptosis
Kurz, T., Terman, A., Gustafsson, B., & Brunk, U. T. (2008) · Histochemistry and Cell Biology · doi:10.1007/s00418-008-0394-y · Cited by 302
Lysosomes and oxidative stress in aging and apoptosis
Kurz, T., Terman, A., Gustafsson, B., & Brunk, U. T. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.01.009 · Cited by 287
Chemical combination effects predict connectivity in biological systems
Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100116 · Cited by 275
Ceramide Interaction with the Respiratory Chain of Heart Mitochondria
Di Paola, M., Cocco, T., & Lorusso, M. (2000) · Biochemistry · doi:10.1021/bi9924415 · Cited by 262
Shachar, D. B., Kahana, N., Kampel, V., Warshawsky, A., & Youdim, M. B. H. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.09.005 · Cited by 246
Iron and neurodegenerative disorders
Thompson, K. J., Shoham, S., & Connor, J. R. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00510-x · Cited by 235 · cited 1×
“…et al., 2008; Rhodes and Ritz, 2008; Schneider and Bhatia, 2012; Schneider et al., 2012; Sian-Hulsmann et al., 2011, 2010; Snyder and Connor, 2009; Thompson et al., 2001; Zecca et al., 2004)] strongly indicates that the metal iron, when unliganded and in various ionic forms, is intimately (Dröge,…”
Autophagy, ageing and apoptosis: The role of oxidative stress and lysosomal iron
Kurz, T., Terman, A., & Brunk, U. T. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.01.013 · Cited by 199 · cited 1×
“The lysosome is the site of most labile iron in the cell [e.g. (Dusek et al., 2012; Fakih et al., 2008, 2009; Gorria et al., 2008; Kurz et al., 2004, 2007, 2008a,b; Persson, 2005; Sahoo et al., 2012; Tenopoulou et al., 2007; Terman et al., 2006; Yu et al., 2003)].”
Gegg, M. E., Cooper, J. M., Schapira, A. H. V., & Taanman, J.-W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004756 · Cited by 198 · cited 1×
“Silencing PINK1 in SH-SY5Y cells led to an increase in mitochondrial dysfunction and oxidative stress (Gegg et al., 2009; Vos et al., 2012).”
Mitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175 · cited 1×
“…2005; Danielson et al., 2011; Dawson and Dawson, 2003; Fato et al., 2008b; Henchcliffe and Beal, 2008; Perier et al., 2007; Schapira et al., 1989; Schapira, 2007; Sterky et al., 2012; Winklhofer and Haass, 2010), increased excitotoxicity, altered calcium homeostasis (Lang, 2007; Maetzler et al.,…”
Robustness as an evolutionary principle
Bornholdt, S., & Sneppen, K. (2000) · Proceedings of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rspb.2000.1280 · Cited by 132
Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent.
Bowern, N., Ramshaw, I. A., Clark, I. A., & Doherty, P. C. (1984) · The Journal of experimental medicine · doi:10.1084/jem.160.5.1532 · Cited by 119 · cited 2×
“, 2008)] and animal models (Adlard et al., 2008; Bolognin et al., 2009a; Bowern et al., 1984; Cheng et al., 2008; Dexter et al., 2011; Ebadi et al., 2002, 2005a; Gal et al., 2009; Kooncumchoo et al., 2006, 2012; Lan and Jiang, 1997; Levenson, 2003; Levenson et al., 2004a; Levites et al., 2001; Mounsey and Teismann, 20…”
Iron: A New Target for Pharmacological Intervention in Neurodegenerative Diseases
Whitnall, M., & Richardson, D. R. (2006) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2006.08.008 · Cited by 113 · cited 1×
“…iron has been shown to be effective in delaying or preventing neurodegeneration by reducing the amount of iron which contributes to oxidative stress (Kaur et al., 2003), indicating possible therapeutic strategies (Jomova and Valko, 2011a; Van der Schyf et al., 2006; Whitnall and Richardson, 2006).”
KURZ, T., LEAKE, A., von ZGLINICKI, T., & BRUNK, U. T. (2004) · Biochemical Journal · doi:10.1042/bj20031029 · Cited by 101 · cited 1×
“The lysosome is the site of most labile iron in the cell [e.g. (Dusek et al., 2012; Fakih et al., 2008, 2009; Gorria et al., 2008; Kurz et al., 2004, 2007, 2008a,b; Persson, 2005; Sahoo et al., 2012; Tenopoulou et al., 2007; Terman et al., 2006; Yu et al., 2003)].”
Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration
Zhang, X., Xie, W., Qu, S., Pan, T., Wang, X., & Le, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.150 · Cited by 87 · cited 1×
“…Mounsey and Teismann, 2012; Mu et al., 2011; Perez et al., 2008; Saini et al., 2010; Shachar et al., 2004; Shi et al., 2010; Ward et al., 2012; Zhang et al., 2005, 2012), a resurgence of pre-clinical and clinical trials in humans is only just beginning to show positive results (Weinreb et…”
Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy
Boelmans, K., Holst, B., Hackius, M., Finsterbusch, J., Gerloff, C., Fiehler, J., & Münchau, A. (2012) · Movement Disorders · doi:10.1002/mds.24926 · Cited by 80 · cited 1×
“A very large literature [e.g. (Barnham and Bush, 2008; Boelmans et al., 2012; Bolognin et al., 2009b; Crichton et al., 2011; Dexter et al., 1989; Galazka-Friedman et al., 2012; Jomova et al., 2010a; Kell, 2009b, 2010b; Mochizuki and Yasuda, 2012; Nunez et al., 2012; Perez et al., 2008; Rhodes and…”
Dopamine-Dependent Iron Toxicity in Cells Derived from Rat Hypothalamus
Paris, I., Martinez-Alvarado, P., Cárdenas, S., Perez-Pastene, C., Graumann, R., Fuentes, P., Olea-Azar, C., Caviedes, P., & Segura-Aguilar, J. (2005) · Chemical Research in Toxicology · doi:10.1021/tx0497144 · Cited by 74
Dopamine complexes of iron in the etiology and pathogenesis of Parkinson’s disease
ARREGUIN, S., NELSON, P., PADWAY, S., SHIRAZI, M., & PIERPONT, C. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2008.09.007 · Cited by 55 · cited 1×
“Iron can also react with dopamine directly in the dopaminergic neurons of the SN to form a toxic complex (Arreguin et al., 2009; Paris et al., 2005) that itself probably catalyses hydroxyl formation.”
Cited by
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
Discerning the Chemistry in Individual Organelles with Small‐Molecule Fluorescent Probes
Xu, W., Zeng, Z., Jiang, J., Chang, Y., & Yuan, L. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201510721 · Cited by 808
Kell, D. B., & Pretorius, E. (2014) · Metallomics · doi:10.1039/c3mt00347g · Cited by 667
Self-citationUnderstanding Dopaminergic Cell Death Pathways in Parkinson Disease
Michel, P. P., Hirsch, E. C., & Hunot, S. (2016) · Neuron · doi:10.1016/j.neuron.2016.03.038 · Cited by 600
The hallmarks of Parkinson's disease
Antony, P. M. A., Diederich, N. J., Krüger, R., & Balling, R. (2013) · The FEBS Journal · doi:10.1111/febs.12335 · Cited by 300
Metadata
- Authors
- Funke, C., Schneider, S. A., Berg, D., & Kell, D. B.
- Venue
- Neurochemistry International
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 62
- Issue
- 5
- Pages
- 637-652
- ISSN
- 0197-0186 (ISSN-L)
- OpenAlex
- W1989846919
- Cited by
- 54
- References
- 63
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.